# Safety and Efficacy of LCI699 in Cushing's Disease Patients

> **NCT01331239** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Cushings Disease
- Cushing Disease

## Interventions

- **DRUG:** LCI699

## Key facts

- **NCT ID:** NCT01331239
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-23
- **Primary completion:** 2019-10-22
- **Final completion:** 2019-10-22
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01331239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01331239, "Safety and Efficacy of LCI699 in Cushing's Disease Patients". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT01331239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*